Company Profile (AI Text)
Name: Entelexo (YC W21)
Canonical URL: https://wefunder.com/entelexo
Updated at: 2026-06-22T05:03:19Z

Tagline: Creating a new class of drugs to address incurable autoimmune diseases
Elevator pitch: We are applying new knowledge of stem cell biology to develop new treatments for autoimmune diseases.

Key claims:
- Total raised on Wefunder: 32890 | citation: https://wefunder.com/entelexo#claim-total-raised
- Total investors: 80 | citation: https://wefunder.com/entelexo#claim-total-investors

Verified facts:
- Total raised on Wefunder: 32890 | observed_at: 2026-06-22T05:03:19Z | expires_at: 2026-06-23T05:03:19Z
- Total investors: 80 | observed_at: 2026-06-22T05:03:19Z | expires_at: 2026-06-23T05:03:19Z

Computed metrics:
- total_amount_raised: 32890
- total_investors: 80
- team_size: 3
- featured_investor_count: 1
- faq_count: 0
- recent_post_count: 0

Quick facts:
- >$1M raised to date, plus $310k on the same terms | citation: https://wefunder.com/entelexo#claim-fact-1
- CEO led the 1st clinical trials in the world evaluating exosomes as a treatment for autoimmune disease | citation: https://wefunder.com/entelexo#claim-fact-2
- Targeting 25M affected by immune-mediated diseases in US, equal to ~$150B in medical costs/year | citation: https://wefunder.com/entelexo#claim-fact-3
- Our intellectual property is patent-protected (patent owned by the Company) | citation: https://wefunder.com/entelexo#claim-fact-4
- Raising $2M for pre-clinical product development and IND enabling animal studies | citation: https://wefunder.com/entelexo#claim-fact-5